Peptide Synthesis & Commercial Drug Product
Opened a £65M, 100,000 sq ft commercial manufacturing facility in March 2025 for oral dose and potent drug products, alongside a separate 28,000 sq ft GMP peptide API synthesis plant (completed 2024) supporting growing demand for peptide therapeutics.